FDA Grants Expedited Review For Potential Aducanumab For Alzheimer
Biogen’s shares were up 10% at $306 before the bell. If approved, aducanumab would be the first treatment designed to…
Biogen’s shares were up 10% at $306 before the bell. If approved, aducanumab would be the first treatment designed to…